Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Double‐Blind Trial

  title={Evaluation of Carisbamate for the Treatment of Migraine in a Randomized, Double‐Blind Trial},
  author={Roger K. Cady and Ninan T. Mathew and Hans Christoph Diener and Peter Hu and Magali Haas and Gerald P. Novak},
  journal={Headache: The Journal of Head and Face Pain},
Objective.— This study explored the dose‐response relationship of carisbamate administered at doses of 100 mg per day, 300 mg per day, or 600 mg per day, in the prevention of migraine. 

Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls

Exercise may be an option for the prophylactic treatment of migraine in patients who do not benefit from or do not want to take daily medication.

Efficacy and Safety of Carisbamate in Patients with Diabetic Neuropathy or Postherpetic Neuralgia: Results from 3 Randomized, Double‐Blind Placebo‐Controlled Trials

Carisbamate, although well tolerated, did not demonstrate efficacy in neuropathic pain across these studies, nor did the active comparator pregabalin (study 3), although multiple secondary end points showed significant improvement in efficacy with carisBamate in studies 1 and 2.

Medicament comprising carisbamate, and use thereof for prevention, alleviation or treatment of pain or epilepsy

The present invention relates to a medicament and a pharmaceutical composition comprising carisbamate and at least one selected from among gabapentin and pregabalin, and use thereof for treating pain or epilepsy.

Antiepileptics in migraine prophylaxis: An updated Cochrane review

Topiramate, sodium valproate and divalproex are effective prophylactic treatments for episodic migraine in adults and there is insufficient evidence to further support the use of gabapentin.

The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments

Considering the detrimental impact that high placebo response can have on clinical trials, it is imperative to find effective solutions to decrease the placebo response and increase assay sensitivity.

A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache

Network meta-analysis found amitriptyline to be better than several other medications including candesartan, fluoxetine, propranolol, topiramate and valproate and no different than atenolol, flunarizine, clomipramine or metoprolol.



Prophylaxis of Migraine with Oral Magnesium: Results From A Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study

High-dose oral magnesium appears to be effective in migraine prophylaxis and duration and intensity of attacks and the drug consumption per attack tended to decrease compared to placebo but failed to be significant.

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.

It is demonstrated that TPM 100 mg/d is effective in migraine prophylaxis and was better tolerated than TPM 200mg/d, and was generally comparable to PROP.

Cyclandelate in the Prophylaxis of Migraine: A Placebo-Controlled Study

The prophylactic action of cyclandelate was investigated in a multicentre, randomized, placebo-controlled, parallel group study and it was not superior to placebo in the Prophylaxis of migraine with regard to parameters usually used in migraine proPHylaxis trials.

Prophylactic Treatment of Migraine with Bisoprolol

Treatment with bisoprolol 5 mg resulted in a significant reduction in the frequency of migraine attacks compared to placebo treatment and treatment had no effect on the duration and severity of the attacks.

Topiramate in migraine prophylaxis

It is demonstrated that TPM 100 mg/d is effective in migraine prophylaxis and was better tolerated than TPM 200mg/d, and was generally comparable to PROP.

Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study

The patterns of medical treatment for migraineurs in the United States are described to describe the patterns of treatment in the country.

Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures

Carisbamate at doses of 300, 800, and 1,600 mg/d was effective as adjunctive therapy for reducing the frequency of partial-onset seizures.

Migraine prophylaxis with divalproex.

Divalproex is an effective prophylactic drug for patients with migraine headaches and is generally well tolerated.

Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura

Lamotrigine was highly effective in reducing migraine aura and migraine attacks and stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.